

Date: February 6, 2023

To,

| BSE Limited | National Stock Exchange of India Limited |
|----------------------------|--|
| Phiroze Jeejeebhoy Towers, | Exchange Plaza, Plot no. C/1, G Block, |
| Dalal Street, | Bandra-Kurla Complex |
| Mumbai- 400 001 | Bandra (E), Mumbai - 400 051 |
| Scrip Code: 543434 | NSE Symbol: SUPRIYA |
| | |

Dear Sir/Madam,

<u>Sub: Intimation of Board Meeting under Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</u>

In terms of Regulation 29 (1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a meeting of the Board of Directors of the Company will be held on Tuesday, February 14, 2023, inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022.

This is further to inform you that with reference to our letter dated December 29, 2022 and in accordance with the provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and the Company's Code of Conduct for Prevention of Insider Trading, the 'Trading Window' for dealing in the securities of the Company shall continue to remain closed till 48 hours after announcement of Unaudited Financial Results for the quarter and nine months ended December 31, 2022.

Kindly take the above said information on your records.

Thanking you,

For Supriya Lifescience Limited

Shweta Singh Company Secretary & Compliance Officer Membership No.: A44973

: A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India. Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: <u>factory@supriyalifescience.com</u>